---
title: "Takeda Pharmaceutical Company Limited (TAK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TAK.US.md"
symbol: "TAK.US"
name: "Takeda Pharmaceutical Company Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-22T03:08:32.605Z"
locales:
  - [en](https://longbridge.com/en/quote/TAK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TAK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TAK.US.md)
---

# Takeda Pharmaceutical Company Limited (TAK.US)

## Company Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.takeda.com](https://www.takeda.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.50)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 44 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -1.16% |  |
| Net Profit YoY | 78.56% |  |
| P/B Ratio | 1.08 |  |
| Dividend Ratio | 1.51% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 52695336270.96 |  |
| Revenue | 29691543506.81 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.61% | C |
| Profit Margin | 4.26% | C |
| Gross Margin | 65.12% | A |
| Revenue YoY | -1.16% | D |
| Net Profit YoY | 78.56% | A |
| Total Assets YoY | 1.71% | C |
| Net Assets YoY | 5.12% | C |
| Cash Flow Margin | 543.09% | A |
| OCF YoY | -1.16% | D |
| Turnover | 0.30 | D |
| Gearing Ratio | 49.69% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Takeda Pharmaceutical Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-1.16%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "78.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.51%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "52695336270.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "29691543506.81",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.61%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "4.26%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "65.12%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-1.16%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "78.56%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.71%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.12%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "543.09%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-1.16%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "49.69%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 41.20 | 52/190 | 202.74 | 69.38 | 50.86 |
| PB | 1.07 | 50/190 | 1.15 | 1.01 | 0.95 |
| PS (TTM) | 1.75 | 46/190 | 1.87 | 1.58 | 1.52 |
| Dividend Yield | 1.53% | 26/190 | 3.67% | 3.17% | 1.93% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.48 |
| Highest Target | 21.93 |
| Lowest Target | 18.76 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TAK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TAK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TAK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TAK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**